Actavis adds new generic products to range

Actavis has expanded its generic product range with the addition of three new off-label therapies.

The pharmacy supplier has introduced Ibandronic acid 50mg tablets, exemestane tablets and a flucloxacillin sugar-free powder for oral solution in syringe format, reports Chemist and Druggist.

Both the Ibandronic acid and exemestane treatments have been released on the first day of patent expiry, which it believes is important for pharmacies that are seeking to expand their margins by selling off-label therapies.

Michael Cann, director of generics at Actavis, said the new product introductions show the company's "dedication to developing a competitively priced, broad portfolio of products with a continued focus on day one patent expiries".

This comes after the firm introduced Repaglinide tablets, its new generic treatment for type 2 diabetes, in the UK and other European nations earlier this month.

An Actavis spokesperson added that further product launches and line extensions will be forthcoming.